The gut microbiota and host health: a new clinical frontier

Over the last 10–15 years, our understanding of the composition and functions of the human gut microbiota has increased exponentially. To a large extent, this has been due to new ‘omic’ technologies that have facilitated large-scale analysis of the genetic and metabolic profile of this microbial community, revealing it to be comparable in influence to a new organ in the body and offering the possibility of a new route for therapeutic intervention. Moreover, it might be more accurate to think of it like an immune system: a collection of cells that work in unison with the host and that can promote health but sometimes initiate disease. This review gives an update on the current knowledge in the area of gut disorders, in particular metabolic syndrome and obesity-related disease, liver disease, IBD and colorectal cancer. The potential of manipulating the gut microbiota in these disorders is assessed, with an examination of the latest and most relevant evidence relating to antibiotics, probiotics, prebiotics, polyphenols and faecal microbiota transplantation.

[1]  Brandi L. Cantarel,et al.  Integrated Metagenomics/Metaproteomics Reveals Human Host-Microbiota Signatures of Crohn's Disease , 2012, PloS one.

[2]  E. Pilozzi,et al.  Alteration of Local Microflora and &agr;-defensins Hyper-production in Colonic Adenoma Mucosa , 2011, Journal of clinical gastroenterology.

[3]  E. El-Omar,et al.  Detection of Campylobacter concisus and Other Campylobacter Species in Colonic Biopsies from Adults with Ulcerative Colitis , 2011, PloS one.

[4]  E. Zoetendal,et al.  Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. , 2015, Gastroenterology.

[5]  Timothy L. Tickle,et al.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment , 2012, Genome Biology.

[6]  D. Lamm,et al.  Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer , 2015, Nature Reviews Urology.

[7]  M. Clifford.  Diet-Derived Phenols in Plasma and Tissues and their Implications for Health , 2004, Planta medica.

[8]  N. Pace,et al.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases , 2007, Proceedings of the National Academy of Sciences.

[9]  P. Edwards,et al.  Pleiotropic roles of bile acids in metabolism. , 2013, Cell metabolism.

[10]  G R Gibson,et al.  Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. , 1995, The Journal of nutrition.

[11]  G. Macfarlane,et al.  Fermentation in the Human Large Intestine: Its Physiologic Consequences and the Potential Contribution of Prebiotics , 2011, Journal of clinical gastroenterology.

[12]  K. Verbeke,et al.  Relevance of protein fermentation to gut health. , 2012, Molecular nutrition & food research.

[13]  Leo Lahti,et al.  Fat, Fiber and Cancer Risk in African Americans and Rural Africans , 2015, Nature Communications.

[14]  R. Knight,et al.  Analysis of the Gut Microbiota in the Old Order Amish and Its Relation to the Metabolic Syndrome , 2012, PloS one.

[15]  D. Sinderen,et al.  Gut microbiota composition correlates with diet and health in the elderly , 2012, Nature.

[16]  M. Bissonnette,et al.  Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway , 2014, Oncogenesis.

[17]  N. Hall,et al.  Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer , 2013, Gut.

[18]  Joi Foss Vogin.  Diet-Microbe Interactions in the Gut, Effects on Human Health and Disease , 2015 .

[19]  S. Ng,et al.  Mechanisms of action of probiotics: Recent advances , 2009, Inflammatory bowel diseases.

[20]  J. Clemente,et al.  Diet Drives Convergence in Gut Microbiome Functions Across Mammalian Phylogeny and Within Humans , 2011, Science.

[21]  Lihua Chen,et al.  Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. , 2013, World journal of gastroenterology.

[22]  Yongzhi Yang,et al.  Analysis of the Intestinal Lumen Microbiota in an Animal Model of Colorectal Cancer , 2014, PloS one.

[23]  Levi Waldron,et al.  Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples , 2012, Genome Biology.

[24]  H. Flint,et al.  The role of “keystone” species in the degradation of recalcitrant substrates , 2013 .

[25]  P. Brigidi,et al.  Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.

[26]  F. Tinahones,et al.  Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. , 2012, The American journal of clinical nutrition.

[27]  Emma Allen-Vercoe,et al.  Co-occurrence of anaerobic bacteria in colorectal carcinomas , 2013, Microbiome.

[28]  F. Bäckhed,et al.  Obesity alters gut microbial ecology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Fredrik H. Karlsson,et al.  Gut metagenome in European women with normal, impaired and diabetic glucose control , 2013, Nature.

[30]  E. Zoetendal,et al.  Molecular ecological tools to decipher the role of our microbial mass in obesity. , 2015, Beneficial microbes.

[31]  J. Talwalkar,et al.  Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis , 2013, BioMed research international.

[32]  J. Hertzberg.  Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection , 2013 .

[33]  S. Rabot,et al.  Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice , 2012, Gut.

[34]  Richard Hansen,et al.  Microbiota of De-Novo Pediatric IBD: Increased Faecalibacterium Prausnitzii and Reduced Bacterial Diversity in Crohn's But Not in Ulcerative Colitis , 2012, The American Journal of Gastroenterology.

[35]  P. Savage,et al.  Liver Autoimmunity Triggered by Microbial Activation of Natural Killer T Cells , 2008, Cell host & microbe.

[36]  N. Pace,et al.  Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. , 2008, Cell host & microbe.

[37]  M. Kremer,et al.  Contribution of Gut Bacteria to Liver Pathobiology , 2010, Gastroenterology research and practice.

[38]  B. Schnabl,et al.  Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. , 2012, World journal of hepatology.

[39]  Lixin Zhu,et al.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.

[40]  W. D. de Vos,et al.  The first 1000 cultured species of the human gastrointestinal microbiota , 2014, FEMS microbiology reviews.

[41]  G. Gao,et al.  Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer Patients , 2013, Microbial Ecology.

[42]  M. Stolte,et al.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine , 2004, Gut.

[43]  Emmanuel Buc,et al.  Colonization of the Human Gut by E. coli and Colorectal Cancer Risk , 2013, Clinical Cancer Research.

[44]  Richard A. Flavell,et al.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.

[45]  Zaid Abdo,et al.  Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas , 2010, Gut microbes.

[46]  Julian Parkhill,et al.  High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease , 2011, BMC Microbiology.

[47]  B. Finlay,et al.  Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. , 2007, Cell host & microbe.

[48]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[49]  E. Zoetendal,et al.  Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. , 2013, The American journal of clinical nutrition.

[50]  H. Flint,et al.  Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. , 2010, Environmental microbiology.

[51]  J. Doré,et al.  Low counts of Faecalibacterium prausnitzii in colitis microbiota , 2009, Inflammatory bowel diseases.

[52]  C. Manichanh,et al.  Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach , 2005, Gut.

[53]  L. Ursell,et al.  Genetically dictated change in host mucus carbohydrate landscape exerts a diet-dependent effect on the gut microbiota , 2013, Proceedings of the National Academy of Sciences.

[54]  E. El-Omar,et al.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? , 2014, World journal of gastroenterology.

[55]  A. Nanji,et al.  Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. , 1993, The American journal of pathology.

[56]  H. Tjalsma,et al.  The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. , 2013, The Lancet. Infectious diseases.

[57]  E. Zoetendal,et al.  The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. , 2015, Journal of Crohn's & colitis.

[58]  M. Blüher.  The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals , 2010, Current opinion in lipidology.

[59]  H. Lochs,et al.  Spatial Organization and Composition of the Mucosal Flora in Patients with Inflammatory Bowel Disease , 2005, Journal of Clinical Microbiology.

[60]  A. Forbes,et al.  Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease , 2005, Gut.

[61]  E. Holmes,et al.  Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. , 2008, Environmental microbiology.

[62]  Glenn R. Gibson,et al.  The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic , 2014 .

[63]  Mathieu Almeida,et al.  Dietary intervention impact on gut microbial gene richness , 2013, Nature.

[64]  E. Zoetendal,et al.  Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. , 2012, Gastroenterology.

[65]  H. Gaskins,et al.  Microbial pathways in colonic sulfur metabolism and links with health and disease , 2012, Front. Physio..

[66]  Zhixiang Zuo,et al.  Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohn's Disease, and Pouchitis: Meta-analysis of Randomized Controlled Trials , 2014, Inflammatory bowel diseases.

[67]  S. Sarin,et al.  Small‐intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease , 2009, Alimentary pharmacology & therapeutics.

[68]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[69]  S. Ng,et al.  Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease , 2011, Gut.

[70]  F. Bushman,et al.  Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes , 2011, Science.

[71]  G. La Torre,et al.  Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease , 2009, Hepatology.

[72]  S. Curbishley,et al.  Immunology of the gut and liver: a love/hate relationship , 2008, Gut.

[73]  V. Somers,et al.  Accuracy of body mass index in diagnosing obesity in the adult general population , 2008, International Journal of Obesity.

[74]  Masoumeh Sikaroodi,et al.  Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[75]  S. Prakash,et al.  Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial , 2012, European Journal of Clinical Nutrition.

[76]  H. Flint,et al.  Human colonic microbiota associated with diet, obesity and weight loss , 2008, International Journal of Obesity.

[77]  Lawrence A. David,et al.  Diet rapidly and reproducibly alters the human gut microbiome , 2013, Nature.

[78]  James B. Mitchell,et al.  Stable isotope- and mass spectrometry-based metabolomics as tools in drug metabolism: a study expanding tempol pharmacology. , 2013, Journal of proteome research.

[79]  M. Omata,et al.  Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. , 1988, Gastroenterology.

[80]  Qiang Feng,et al.  A metagenome-wide association study of gut microbiota in type 2 diabetes , 2012, Nature.

[81]  A. Rudensky,et al.  Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation , 2013, Nature.

[82]  Zeneng Wang,et al.  Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk , 2013 .

[83]  C. Constantinidou,et al.  Probing the microbiota in PSC : the gut adherent microbiota of PSC-IBD is distinct to that of IBD and controls , 2014 .

[84]  D. Pardoll,et al.  Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. , 2011, The Journal of infectious diseases.

[85]  C. Constantinidou,et al.  The gut-adherent microbiota of PSC–IBD is distinct to that of IBD , 2016, Gut.

[86]  D. Rubin,et al.  Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. , 2014, Journal of Crohn's & colitis.

[87]  P. Vítek,et al.  Probiotics in hepatology. , 2011, World journal of gastroenterology.

[88]  A. Gasbarrini,et al.  Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study , 2010, The American Journal of Gastroenterology.

[89]  R. Genco,et al.  Interactions between Periodontal Bacteria and Human Oral Epithelial Cells: Fusobacterium nucleatum Adheres to and Invades Epithelial Cells , 2000, Infection and Immunity.

[90]  E. Drenick,et al.  Hepatic steatosis after intestinal bypass--prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. , 1982, Gastroenterology.

[91]  Manolito Torralba,et al.  Enteric dysbiosis associated with a mouse model of alcoholic liver disease , 2011, Hepatology.

[92]  Belgin Dogan,et al.  Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota , 2012, Science.

[93]  N. Barnich,et al.  E. coli-mediated gut inflammation in genetically predisposed Crohn's disease patients. , 2013, Pathologie-biologie.

[94]  M. Huycke,et al.  Commensal bacteria drive endogenous transformation and tumour stem cell marker expression through a bystander effect , 2014, Gut.

[95]  G. Hajishengallis,et al.  The keystone-pathogen hypothesis , 2012, Nature Reviews Microbiology.

[96]  M. Vatn,et al.  Dominant Fecal Microbiota in Newly Diagnosed Untreated Inflammatory Bowel Disease Patients , 2013, Gastroenterology research and practice.

[97]  Bas E Dutilh,et al.  A bacterial driver–passenger model for colorectal cancer: beyond the usual suspects , 2012, Nature Reviews Microbiology.

[98]  Jeroen Raes,et al.  A metagenomic insight into our gut's microbiome , 2012, Gut.

[99]  M. R. Rubinstein,et al.  Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. , 2013, Cell host & microbe.

[100]  R. Russell,et al.  Decline in Presumptively Protective Gut Bacterial Species and Metabolites Are Paradoxically Associated with Disease Improvement in Pediatric Crohn’s Disease During Enteral Nutrition , 2014, Inflammatory bowel diseases.

[101]  M. Surette,et al.  Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. , 2015, Gastroenterology.

[102]  H. Flint,et al.  Role of the gut microbiota in nutrition and health , 2018, British Medical Journal.

[103]  A. Cederborg,et al.  Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis , 2005, Scandinavian journal of gastroenterology.

[104]  T. Sharpton,et al.  "Gut". , 2022, Canadian Medical Association journal.

[105]  P. Rutgeerts,et al.  Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. , 1995, Gastroenterology.

[106]  R. Francés,et al.  Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[107]  Jenny Sauk,et al.  Disease-Specific Alterations in the Enteric Virome in Inflammatory Bowel Disease , 2015, Cell.

[108]  T. Dinan,et al.  Minireview: Gut microbiota: the neglected endocrine organ. , 2014, Molecular endocrinology.

[109]  P. Bork,et al.  Richness of human gut microbiome correlates with metabolic markers , 2013, Nature.

[110]  N. Hall,et al.  Towards the Human Colorectal Cancer Microbiome , 2011, PloS one.

[111]  K. Cox,et al.  Long-term Treatment of Primary Sclerosing Cholangitis in Children With Oral Vancomycin: An Immunomodulating Antibiotic , 2008, Journal of pediatric gastroenterology and nutrition.

[112]  Cynthia L Sears,et al.  A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses , 2009, Nature Medicine.

[113]  Peer Bork,et al.  The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates , 2012, The ISME Journal.